How many drugs treat Psychotic disorder?

Drug Landscape tracks 5 marketed treatments for Psychotic disorder (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/psychotic-disorder.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Psychotic disorder — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psychotic disorder (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Psychotic disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Prolixin Decanoate	FLUPHENAZINE DECANOATE	Bristol-Myers Squibb	Phenothiazine	D(2) dopamine receptor	1972-01-01
Haldol	haloperidol	Johnson & Johnson (Janssen)	Typical Antipsychotic [EPC]	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A	1967-04-12
Moditen Enanthate	FLUPHENAZINE ENANTHATE	Bristol-Myers Squibb	Phenothiazine	D(3) dopamine receptor	1967-01-01
Tindal	ACETOPHENAZINE	Merck & Co.	acetophenazine	D(2) dopamine receptor	1961-01-01
Thorazine	chlorpromazine	Generic (originally Rhône-Poulenc/Sanofi)	Typical antipsychotic (first-generation, phenothiazine)	Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E	1954-03-26

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Psychotic disorder
Bristol-Myers Squibb · 2 drugs in Psychotic disorder
Generic (originally Rhône-Poulenc/Sanofi) · 1 drug in Psychotic disorder
Johnson & Johnson (Janssen) · 1 drug in Psychotic disorder
Merck & Co. · 1 drug in Psychotic disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Psychotic disorder:

Cite this brief

Drug Landscape (2026). Psychotic disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/psychotic-disorder. Accessed 2026-06-10.

Psychotic disorder full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing